Meningioma

Meningiomas are tumors that originate from the meninges, the protective layers surrounding the brain and spinal cord. The development of effective drug treatments for recurrent and treatment-refractory meningiomas has been challenged and limited by a variety of factors. Alfa Cytology is committed to pioneering new therapeutic approaches for meningioma treatment for our clients.

Introduction to Meningioma

The meninges are the membranes that surround the brain and spinal cord and a meningioma is a tumor that develops from the meninges. Meningiomas account for approximately 27% of primary brain tumors and are very common tumors of this type. Most meningiomas (90%) are classified as benign tumors, with the remaining 10% being atypical or malignant. In many cases, benign meningiomas grow slowly. This means that depending on the location of the meningioma, it may have reached a relatively large size before it causes symptoms.

Fig.1 Typical mutations by WHO classification and anatomical location. (Al-Rashed M., et al., 2020)

Therapeutic Development for Meningioma

The mainstay of meningioma treatment is a combination of radiotherapy and surgery, but suffers from low efficacy, short response times to treatment, lack of uniform response criteria, and a limited role for systemic therapy. As with other primary and metastatic brain tumors, the future of immune-based therapeutic approaches to meningiomas remains promising.

Our Services

At Alfa Cytology, we offer a comprehensive range of services designed to facilitate CNS lymphoma diagnostics and therapy development. Our team provides extensive support throughout the drug development process, from initial screening of compounds to detailed pharmacokinetic and pharmacodynamic studies.

Therapeutics Development

• Small Molecule Drug
• Radionuclide Therapy
• Therapeutic Antibody
• Peptide Drug
• Cell Therapy
• Gene Therapy
• Oncolytic Virotherapy
• Vaccine

Modeling Services

• Cell Line Development
• Organoids and Organ Chip Models
• Blood Brain Barrier Models
• Xenograft Models
• Syngeneic Models
• Virus-induced Models
• Transgenic Models
• Metastatic Models

Preclinical Research

• In Vitro Efficacy Evaluation
• In Vivo Efficacy Evaluation
• In Vitro ADME
• In Vivo PK
• Safety Assessment

Diagnostic Development

• Omics Analysis
• Cell Analysis
• Tissue Analysis
• Cytokine Analysis
• Chemokine Analysis
• Growth Factor Analysis
• Primary Immune Cell Analysis

Contact Us

With advances in genomics and the identification of driver mutations, Alfa Cytology has helped researchers in this field to progressively advance their research into targeted drugs. Considering the research on new drugs, identifying and understanding new signaling pathways and factors will hopefully provide ideas for drug development. Please feel free to contact us to advance trials and accelerate the development of new therapies for meningioma patients.

Reference

1. Al-Rashed M.; et al. (2020). Recent Advances in Meningioma Immunogenetics[J]. Front Oncol. 8, 9: 1472.